These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 37822267)

  • 1. Economic evaluations of alcohol pharmacotherapy: Systematic review of economic evaluations of pharmacotherapy for the treatment of alcohol use disorder.
    Higginbotham B; Perez JK; Louie E; Haber PS; Lubman D; Arunogiri S; Chatterton ML; Morley KC
    Aust N Z J Psychiatry; 2024 Feb; 58(2):117-133. PubMed ID: 37822267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
    Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.
    Greene MC; Kane J; Alto M; Giusto A; Lovero K; Stockton M; McClendon J; Nicholson T; Wainberg ML; Johnson RM; Tol WA
    Cochrane Database Syst Rev; 2023 May; 5(5):CD013350. PubMed ID: 37158538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
    McPheeters M; O'Connor EA; Riley S; Kennedy SM; Voisin C; Kuznacic K; Coffey CP; Edlund MD; Bobashev G; Jonas DE
    JAMA; 2023 Nov; 330(17):1653-1665. PubMed ID: 37934220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for evaluating the economic value of drugs in alcohol dependence treatment.
    Schwappach D; Popova S; Mohapatra S; Patra J; Godinho A; Rehm J
    Drug Alcohol Depend; 2012 May; 122(3):165-73. PubMed ID: 21924845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Genotype-Guided Treatment Allocation in Patients with Alcohol Use Disorders Using Naltrexone or Acamprosate, Using a Modeling Approach.
    Sluiter RL; Kievit W; van der Wilt GJ; Schene AH; Teichert M; Coenen MJH; Schellekens A
    Eur Addict Res; 2018; 24(5):245-254. PubMed ID: 30384381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
    Avanceña ALV; Miller N; Uttal SE; Hutton DW; Mellinger JL
    J Hepatol; 2021 Jun; 74(6):1286-1294. PubMed ID: 33326815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to increase implementation of pharmacotherapy for alcohol use disorders: a structured review of care delivery and implementation interventions.
    Williams EC; Matson TE; Harris AHS
    Addict Sci Clin Pract; 2019 Feb; 14(1):6. PubMed ID: 30744686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baclofen for alcohol use disorder.
    Agabio R; Saulle R; Rösner S; Minozzi S
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012557. PubMed ID: 36637087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of pharmacotherapy for alcohol use disorder treatment in primary care settings: A scoping review.
    Hyland CJ; McDowell MJ; Bain PA; Huskamp HA; Busch AB
    J Subst Abuse Treat; 2023 Jan; 144():108919. PubMed ID: 36332528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol pharmacotherapy dispensing trends in Australia between 2006 and 2023.
    Quintrell E; Page A; Wyrwoll C; Larcombe A; Preen DB; Almeida O; Etherton-Beer C; Kelty E
    Alcohol Alcohol; 2024 Jul; 59(5):. PubMed ID: 39242103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model.
    Laramée P; Brodtkorb TH; Rahhali N; Knight C; Barbosa C; François C; Toumi M; Daeppen JB; Rehm J
    BMJ Open; 2014 Sep; 4(9):e005376. PubMed ID: 25227627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.
    Donoghue K; Elzerbi C; Saunders R; Whittington C; Pilling S; Drummond C
    Addiction; 2015 Jun; 110(6):920-30. PubMed ID: 25664494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY
    Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive Medication Management and Contingency Management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT.
    Donoghue K; Boniface S; Brobbin E; Byford S; Coleman R; Coulton S; Day E; Dhital R; Farid A; Hermann L; Jordan A; Kimergård A; Koutsou ML; Lingford-Hughes A; Marsden J; Neale J; O'Neill A; Phillips T; Shearer J; Sinclair J; Smith J; Strang J; Weinman J; Whittlesea C; Widyaratna K; Drummond C
    Health Technol Assess; 2023 Oct; 27(22):1-88. PubMed ID: 37924307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cost Effectiveness of Nalmefene for Reduction of Alcohol Consumption in Alcohol-Dependent Patients with High or Very High Drinking-Risk Levels from a UK Societal Perspective.
    Brodtkorb TH; Bell M; Irving AH; Laramée P
    CNS Drugs; 2016 Feb; 30(2):163-77. PubMed ID: 26879458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New pharmacotherapies for alcohol dependence.
    Graham R; Wodak AD; Whelan G
    Med J Aust; 2002 Jul; 177(2):103-7. PubMed ID: 12098353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis.
    Jonas DE; Amick HR; Feltner C; Bobashev G; Thomas K; Wines R; Kim MM; Shanahan E; Gass CE; Rowe CJ; Garbutt JC
    JAMA; 2014 May; 311(18):1889-900. PubMed ID: 24825644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAEM GRACE: Anti-craving medications for alcohol use disorder treatment in the emergency department: A systematic review of direct evidence.
    Punia K; Scott W; Manuja K; Sabbineni M; Campbell K; Balodis IM; MacKillop J
    Acad Emerg Med; 2024 May; 31(5):504-514. PubMed ID: 37735346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological treatment of alcohol dependence: a review of the evidence.
    Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
    JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.